Literature DB >> 21658053

Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema.

Torkil Menné1, Jeanne D Johansen, Mette Sommerlund, Niels K Veien.   

Abstract

BACKGROUND: Classification of hand eczema has traditionally been based both on aetiology and clinical appearance. For 20% of cases, the aetiology is unknown.
OBJECTIVES: To suggest a classification based on well-defined aetiology as well as on predefined clinical patterns and on the dynamics of hand eczema.
METHODS: Literature studies and discussions among members of the Danish Contact Dermatitis Group.
RESULTS: Criteria are given for the aetiological diagnoses of allergic contact dermatitis of the hands, irritant contact dermatitis of the hands, protein contact dermatitis of the hands, atopic hand eczema and aetiologically unclassifiable hand eczema. Six different clinical patterns are described and illustrated. Suggestions for general treatment principles are given.
CONCLUSION: Operational guidelines for the diagnosis and treatment of hand eczema are described.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658053     DOI: 10.1111/j.1600-0536.2011.01915.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  22 in total

1.  Sociodemographic and clinical profile of patients with occupational contact dermatitis seen at a work-related dermatology service, 2000 - 2014.

Authors:  Maria das Graças Mota Melo; Ana Luiza Castro Fernandes Villarinho; Iuri da Costa Leite
Journal:  An Bras Dermatol       Date:  2019-05-09       Impact factor: 1.896

2.  Successful treatment of refractory chronic hand eczema with calcipotriol/betamethasone ointment: A report of three cases.

Authors:  Min Yang; Jian-Min Chang
Journal:  Exp Ther Med       Date:  2015-09-04       Impact factor: 2.447

3.  Chronic hand eczema--self-management and prognosis: a study protocol for a randomised clinical trial.

Authors:  Annette Mollerup; Niels Kren Veien; Jeanne Duus Johansen
Journal:  BMC Dermatol       Date:  2012-06-12

4.  Efficacy and Safety of Treatment with Oral Alitretinoin and Oral Cyclosporine for Chronic Hand Eczema: A Retrospective Review of 118 Cases.

Authors:  Ye Ji Jang; Ji Ha Yoon; Eun Joo Park; Kwang Joong Kim; Kwang Ho Kim
Journal:  Acta Derm Venereol       Date:  2020-01-30       Impact factor: 3.875

5.  Interventions for hand eczema.

Authors:  Wietske Andrea Christoffers; Pieter-Jan Coenraads; Åke Svensson; Thomas L Diepgen; Janine L Dickinson-Blok; Jun Xia; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-04-26

6.  Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients.

Authors:  Hyoung Il Kwon; Jeong Eun Kim; Joo Yeon Ko; Young Suck Ro
Journal:  Ann Dermatol       Date:  2016-05-25       Impact factor: 1.444

7.  Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures.

Authors:  Alexander Egeberg; Peter Schwarz; Torben Harsløf; Yuki M F Andersen; Anton Pottegård; Jesper Hallas; Jacob P Thyssen
Journal:  JAMA Dermatol       Date:  2021-03-01       Impact factor: 10.282

8.  Study protocol: efficacy of oral alitretinoin versus oral cyclosporine A in patients with severe recurrent vesicular hand eczema (ALICsA): a randomised prospective open-label trial with blinded outcome assessment.

Authors:  Jart Ate Franke Oosterhaven; Marie Louise Anna Schuttelaar
Journal:  BMJ Open       Date:  2018-07-11       Impact factor: 2.692

9.  Presenteeism in a Dutch hand eczema population-a cross-sectional survey.

Authors:  Jart A F Oosterhaven; Peter A Flach; Ute Bültmann; Marie L A Schuttelaar
Journal:  Contact Dermatitis       Date:  2018-04-01       Impact factor: 6.600

10.  2020 Korean Consensus Guidelines for Diagnosis and Treatment of Chronic Hand Eczema.

Authors:  Hee Joo Kim; Chul Hwan Bang; Hye One Kim; Dong Hoon Lee; Joo Yeon Ko; Eun Joo Park; Sang Wook Son; Young Suk Ro
Journal:  Ann Dermatol       Date:  2021-07-01       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.